blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3202420

EP3202420 - TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.01.2021
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  31.01.2020
FormerGrant of patent is intended
Status updated on  14.04.2019
FormerRequest for examination was made
Status updated on  28.03.2019
FormerGrant of patent is intended
Status updated on  26.07.2018
FormerRequest for examination was made
Status updated on  07.07.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Besins Healthcare Luxembourg SARL
2-8 rue Julien Vesque
2668 Luxembourg / LU
[2017/32]
Inventor(s)01 / Masini-Eteve, Valérie
4 rue Pierre Loti
92340 Bourg La Reine / FR
 [2017/32]
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2017/32]
Application number, filing date17157911.309.12.2009
[2017/32]
Priority number, dateEP2008030592411.12.2008         Original published format: EP 08305924
US20080121848P11.12.2008         Original published format: US 121848 P
[2017/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3202420
Date:09.08.2017
Language:EN
[2017/32]
Type: B1 Patent specification 
No.:EP3202420
Date:04.03.2020
Language:EN
[2020/10]
Search report(s)(Supplementary) European search report - dispatched on:EP21.06.2017
ClassificationIPC:A61K9/06, A61K47/10, A61K47/12, A61K31/138, A61P35/00
[2018/33]
CPC:
A61K9/0014 (EP,US); A61K31/138 (EP,US); A61K31/4535 (EP,US);
A61K9/0041 (EP,US); A61K9/06 (EP,US); A61P35/00 (EP);
A61P5/30 (EP); A61K47/10 (EP,US); A61K47/12 (EP,US) (-)
Former IPC [2017/32]A61K47/10, A61K47/12, A61K31/138, A61K31/4535, A61P35/00, A61K9/06
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/32]
TitleGerman:TRANSDERMALE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT EINEM SERM[2017/32]
English:TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM[2017/32]
French:COMPOSITIONS PHARMACEUTIQUES TRANSDERMIQUES COMPORTANT UN STROGÈNE SERM[2017/32]
Examination procedure24.02.2017Examination requested  [2017/32]
24.02.2017Date on which the examining division has become responsible
08.02.2018Amendment by applicant (claims and/or description)
27.07.2018Communication of intention to grant the patent
21.03.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.04.2019Communication of intention to grant the patent
10.10.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
02.12.2019Fee for grant paid
02.12.2019Fee for publishing/printing paid
02.12.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09764869.5  / EP2373305
Divisional application(s)EP20151652.3  / EP3656376
Opposition(s)07.12.2020No opposition filed within time limit [2021/06]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
02.12.2019Request for further processing filed
02.12.2019Full payment received (date of receipt of payment)
Request granted
12.12.2019Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
21.03.2019Request for further processing filed
21.03.2019Full payment received (date of receipt of payment)
Request granted
03.04.2019Decision despatched
Fees paidRenewal fee
24.02.2017Renewal fee patent year 03
24.02.2017Renewal fee patent year 04
24.02.2017Renewal fee patent year 05
24.02.2017Renewal fee patent year 06
24.02.2017Renewal fee patent year 07
24.02.2017Renewal fee patent year 08
24.11.2017Renewal fee patent year 09
28.11.2018Renewal fee patent year 10
04.12.2019Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY04.03.2020
CZ04.03.2020
EE04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
MK04.03.2020
MT04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
[2022/33]
Former [2022/28]CY04.03.2020
CZ04.03.2020
EE04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
MT04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/50]CZ04.03.2020
EE04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/49]CZ04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/48]HR04.03.2020
LT04.03.2020
LV04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/47]HR04.03.2020
LT04.03.2020
LV04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/46]HR04.03.2020
LV04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/39]HR04.03.2020
LV04.03.2020
BG04.06.2020
GR05.06.2020
Former [2020/38]HR04.03.2020
LV04.03.2020
GR05.06.2020
Former [2020/37]HR04.03.2020
LV04.03.2020
Documents cited:Search[Y]WO9924041  (CELLEGY PHARMA INC [US], et al) [Y] 1-9 * the whole document *;
 [Y]US2004175416  (TARAVELLA BRIGITTE [FR], et al) [Y] 1-9 * page 1, paragraphs 12,15-17 * * page 2, paragraphs 27-34 * * page 3, paragraphs 45-47 * * claims 1-21 *;
 [Y]WO2008070463  (JINA PHARMACEUTICALS INC [US], et al) [Y] 1-9 * claims 24-27,32 *;
 [A]  - YOUNG CHAI LIM ET AL, "Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, (20050501), vol. 55, no. 5, ISSN 1432-0843, pages 471 - 478, XP019334143 [A] 1-9 * page 472, column L, paragraph L - page 472, column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1007/s00280-004-0926-7
 [A]  - LEE K-H ET AL, "Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, (20030705), vol. 791, no. 1-2, ISSN 1570-0232, pages 245 - 253, XP004428049 [A] 1-9 * page 247, column L, paragraph L - page 247, column R, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S1570-0232(03)00218-6
 [A]  - MICHAEL D JOHNSON ET AL, "Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20040501), vol. 85, no. 2, ISSN 1573-7217, pages 151 - 159, XP019274612 [A] 1-9 * the whole document *
by applicantWO9527569
 WO9615045
 US5630531
    - POTTS; GUY, PHARM RES., (1992), vol. 9, no. 5, pages 663 - 9
    - CLEEK; BUNGE, PHARM RES, (1993), vol. 10, no. 4, pages 497 - 506
    - BALAKIN ET AL., CURRENT MEDICINAL CHEMISTRY, (2006), vol. 13, pages 223 - 241
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.